Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.
Enzyme linked immunosorbent assay (ELISA) has been widely used to measure antibody titers for evaluating the immunogenicity of a vaccine. However, there is as yet no generally accepted way of expressing the ELISA results in the case of experimental vaccines, since there is usually no uniform standard. Both end point and single dilution methods have significant disadvantages. In this paper, we obtained reproducible data with fewer dilutions of samples by addition of serially diluted standard serum to each ELISA plate. Since this ELISA method gives reliable antibody titer with less labor than other methods, it can strongly support vaccine development.
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA. kmiura@niaid.nih.gov <kmiura@niaid.nih.gov>
Kazutoyo
K
Miura
Andrew C
AC
Orcutt
Olga V
OV
Muratova
Louis H
LH
Miller
Allan
A
Saul
Carole A
CA
Long
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods* / Q000592:standards*; D008253:Macaca mulatta; D017780:Malaria Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D015203:Reproducibility of Results
D000913:Antibodies, Protozoan; D017780:Malaria Vaccines